- All
- Product Name
- Product Keyword
- Product Model
- Product Summary
- Product Description
- Multi Field Search
The current pipeline features a diverse range of assets, including antibody drugs, small molecules, and ADCs targeting various cancers and autoimmune diseases from preclinical to Phase II.
We have also selected few commercial stage products markets in China open for licensing.
Interested in one of our innovative pipelines? Let's discuss your licensing opportunities in depth. Schedule a meeting with Unibest experts to explore how we can collaborate on bringing cutting-edge pharmaceuticals to global markets.
With the development of chemotherapy agents, we've witnessed remarkable strides in the development of chemotherapy agents, resulting in improved efficacy and reduced side effects. However, a critical challenge persists that demands our attention: the management of chemotherapy-induced thrombocytopenia.
Thrombolytic drugs play a crucial role in treating various venous and arterial thromboembolic conditions, particularly acute myocardial infarction.
With the development of chemotherapy agents, we've witnessed remarkable strides in the development of chemotherapy agents, resulting in improved efficacy and reduced side effects. However, a critical challenge persists that demands our attention: the management of chemotherapy-induced thrombocytopenia.
